VBI Vaccines Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 8 of 8 Posts
Week In Review: China Pharmas Announce Deals Worth $1.5 Billion
Article By: ChinaBio® Today Saturday, December 8, 2018 4:21 PM EST
WuXi AppTec, China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range (see story). In May, WuXi became a public company by completing a $328 million IPO in Shanghai.
In this article: RVNC, VBIV, CASI, SPPI
Read
VBI Calls Globes Article 'False' And 'Gross Mischaracterization' Of Facts
Article By: The Fly Sunday, September 16, 2018 6:10 PM EST
VBI Vaccines issued a statement after being the subject of an article published in Israel's Globes on September 12, written by Gali Weinreb, alleging that VBI failed to meet its responsibilities of disclosure regarding a court case in Israel.
In this article: VBIV
Read
Here's What Markets Have Missed By Overlooking The VBI Vaccines CMV News
Article By: Samuel Rae Tuesday, August 15, 2017 11:13 AM EST
Here's a look at the latest data from VBI Vaccines' CMV trial with a discussion of what to look out for next from the program.
In this article: VBIV
Read
E VBI Vaccines: Hidden Vaccine Gem
Article By: Stone Fox Capital Thursday, July 13, 2017 9:05 AM EST
VBI Vaccines is starting Phase III trials for a vaccine approved in multiple countries while the stock trades near the recent lows providing a large catalyst for the stock.
In this article: VBIV Also: DVAX
Read
E An Update On VBI Vaccines Inc: What's Happened And What It Means
Article By: Samuel Rae Thursday, April 20, 2017 6:06 PM EST
Here's an update to my recent coverage of vaccine-focused biotechnology play VBI Vaccines. What's changed since the last time I looked at the company, and how does it affect shareholders going forward?
In this article: VBIV Also: DVAX
Read
E Breaking Down VBI Vaccines' Pipeline: Descriptions And Catalysts
Article By: Samuel Rae Saturday, February 18, 2017 1:12 PM EST
Here's a look at VBI Vaccines' (VBIV) pipeline and the events that should drive value for the company going forward; with caveats.
In this article: GSK, SNY, VBIV Also: OPK
Read
E VBI Vaccines – An Idea For Investors Who Want To Avoid The Index Fund Bubble
Article By: SuperInvestor Bulletin Sunday, November 6, 2016 2:22 PM EST
The current bull market is beyond long in the tooth but there are opportunities outside of index fund stocks. The biotech/pharma area of the market is one that could present opportunity.
In this article: VBIV Also: IBB, DVAX
Read
E VBI Vaccines – The Leading Product In The Race For A $3 Billion Market
Article By: SuperInvestor Bulletin Tuesday, July 26, 2016 10:17 PM EST
A recent merger adds some diversification and a strong shareholder base provides capital support for this small company that is worth watching. That said, there is risk.
In this article: VBIV
Read
1 to 8 of 8 Posts